Skip to main content
. 2021 Mar 25;11(4):492. doi: 10.3390/biom11040492

Table 3.

Clinical trials evaluating AR degradation therapy for the treatment of PCa.

Agents Clinical Phase Identifier Indication Primary Endpoints
ARV-110 I NCT03888612 [115] mCRPC Dose-limiting toxicity, AE, PSA response

AE: adverse event; mCRPC: metastatic castration-resistant prostate cancer; PSA: prostate-specific antigen.